Epeius' prostate cancer drug fast-tracked

Epeius Biotechnologies' lead product, Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The drug is currently in Phase II trials. Release

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.